Daniel-Paul Bednarík, Ph.D. Email & Phone Number

Highland, MD, US

Currently assisting with the financing and technology development for the new company in a contract consulting position.

Gaithersburg, M.D, US

I am serving as a molecular and protein design consultant.

Philadelphia, PA, US

Focused on the translational biology of heart function and disease states.

NexImmune, is an early stage biopharmaceutical company, grounds its novel technology on the discoveries from the laboratory of Drs. Jonathan Schneck and Mathias Oelke of The Johns Hopkins University, both Scientific Co-founders of NexImmune, that reports the development of a new approach for adoptive cellular therapy. In this study artificial Antigen.

NexImmune, an early stage biopharmaceutical company, grounds its novel technology on the discoveries from the laboratory of Dr. Jonathan Schneck of The Johns Hopkins University, a Scientific Co-founder of NexImmune, that reports the development of a new approach for adoptive cellular therapy. In this study artificial Antigen Presenting Cells (aAPC) were.

Bozeman, Montana, US

Microbion’s bismuth-thiol (BT) family of compounds have potent, broad spectrum efficacy against all antibiotic resistant bacteria tested to date. Additionally they have the highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic.

Silver Spring, MD, US

BioIT is a Silver Spring Maryland-based software company specializing in Biotechnology applications, providing a novel line of Portal Products. The founders of BioIT originated from Human Genome Sciences, Inc. (HGS) where the CIO, Michael Fannon, served as the primary architect and designer of that company's cutting edge bioinformatic database and genomics.

Development of stable cell lines for company's RCB and MCB. Expression of nicotine monoclonal antibodies that facilitate smoking cessation.

Germantown, Maryland, US

Promoted to Vice President in August, 2013 #Daniel Bednarik -- Oversees the operations of the company's Molecular Engineering Unit and synthetic biology programs, with emphasis on new gene switch designs and their translation to immuno-oncology and adoptive T-cell therapies (CAR-T). Works closely with the Health Sector Division head and Senior Management.

Germantown, Maryland, US

Oversees the company's Molecular Engineering Unit and program. Works closely with the COO, CSO, President of the Human Therapeutics Division (HTD), Senior Director of Translational Research, Business Development, and Cell Engineering Unit (CEU). The MEU employs Intrexon's proprietary "Ultravector Technology" that grounds the company's commercial efforts.

I was acquired by Cardiome initially as a consultant to transition the Artesian assets into the company for two years, then hired by the company. I worked for Cardiome in total for 7 years. Cardiome is a research-based biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the quality of.

Post-acquisition responsibilities included transition of CRPM and BRPM programs into Cardiome Pharma Corp., acting as Program Manager and designing new animal studies for therapeutic compound validation.

The company's lead siRNA and antisense DNA delivery product, Versadel, is undergoing pre-clinical testing with the intention of partnering with major pharmas. My role for Ablitech is to establish and organize the Scientific Advisory Board (SAB) and assist in the critique of ongoing scientific projects.

Indel Therapeutics Inc. is a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs that focus on curing difficult-to-treat and hospital-acquired infections. These programs are based on Indel’s.

NX PharmaGen’s groundbreaking technologies are paving the way for patients to realize the promise of personalized medicine in cancer and other diseases. The company employs a novel approach to predictive molecular diagnostics by profiling a unique class of biological messengers called "exosomes" or "microvesicles". My role has been to support the.

Paris, FR

Directed new business development efforts, partnering, and translation of corporate technology to practice in the business sector. Worked directly with Vice President, Business Development and Vice President of R&D to execute database partnering opportunities.

Consulting for drug development.

Served as co-founder of company spin out from Gene Logic, Inc. in 2002. Quickly defined relationships between dysregulation of gene expression and small molecule SAR. The program led to two therapeutic classes of molecules designed to restore ejection of blood to the failing heart while suppressing beta-agonist pathways. This led to a rapid exit via sale.

Gaithersburg, MD, US

Dr. Bednarik created the largest known cardiovascular gene expression database for Gene Logic, which served as a prized source of cardiovascular disease data for multiple pharma companies, and grounded the basis for founding Artesian Therapeutics. This database integrated unique personal and clinical biosample attributes with changes in gene expression in.

Pre-clinical study development and reporting for the medical device and pharmaceutical industry.

Served as molecular biologist and bioinformatics scientist - Discovery, characterization, and patenting of novel genes for development of therapeutic proteins.

Msc, Phd, Biochemistry

Oncology Fellow, Oncology And Cancer Biology/Virology

Ba, Biology

High School Diploma